AAA USA

Advanced Accelerator Applications (AAA), a Novartis company, is a leader in the field of targeted radioligand therapy (RLT) and precision radiopharmaceuticals. The company develops, produces, and commercializes molecular nuclear medicines for the treatment of oncology indications, most notably Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer. AAA operates an extensive network of manufacturing sites across Europe and the United States to support the production of short-lived radioactive isotopes. Their approach combines a targeting compound (ligand) with a therapeutic radioisotope to deliver radiation directly to cancer cells. The company's portfolio also includes diagnostic imaging agents that help identify patients suitable for their therapeutic counterparts.